title: Making the case for biotechnology Reinsurance (BIO-RE).
abstract: The inherent difficulty of sustaining the rate of growth in healthcare spending may make biologics a touchstone for government intervention. The author proposes a combined cost-management and care-delivery standard that could lessen that threat.
authors.forename: Bruce
authors.initials: B
authors.lastname: Pyenson